Pediatric Infection and Vaccine

The Korean Society of Pediatric Infectious Diseases (대한소아감염학회)
권호 표지
DOI QR코드

DOI QR Code

Etiology of Bacteremia in Children with Hemato-oncologic Diseases from a Single Center from 2011 to 2015

단일 기관에서의 소아 혈액종양 환자에서 발생한 균혈증의 원인균 및 임상 양상: 2011-2015년

  • Park, Ji Young (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Yun, Ki Wook (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Kang, Hyoung Jin (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Park, Kyung Duk (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Shin, Hee Young (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Lee, Hoan Jong (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine) ;
  • Choi, Eun Hwa (Department of Pediatrics, Seoul National University Children's Hospital, Seoul National University College of Medicine)
  • 박지영 (서울대학교 어린이병원 소아청소년과) ;
  • 윤기욱 (서울대학교 어린이병원 소아청소년과) ;
  • 강형진 (서울대학교 어린이병원 소아청소년과) ;
  • 박경덕 (서울대학교 어린이병원 소아청소년과) ;
  • 신희영 (서울대학교 어린이병원 소아청소년과) ;
  • 이환종 (서울대학교 어린이병원 소아청소년과) ;
  • 최은화 (서울대학교 어린이병원 소아청소년과)
  • Received : 2016.12.07
  • Accepted : 2017.03.15
  • Published : 2017.08.25
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to identify the pathogens of blood stream infection (BSI) in children with hemato-oncologic disorders, to analyze susceptibility patterns of microorganisms to guide empirical antimicrobial therapy, and to compare temporal trends of the pathogen and antimicrobial susceptibility with those of previous studies. Methods: We retrospectively analyzed the medical records of children with hemato-oncologic disorders whose blood culture grew pathogens at the Seoul National University Children's Hospital between 2011 and 2015. Results: A total of 167 patients developed 221 episodes of bacteremia. Among 229 pathogens, gram-negative bacteria (GNB) accounted for 69.0% (64.0% in 2002 to 2005, 63.4% in 2006 to 2010); gram-positive bacteria (GPB) accounted for 28.8% (31.3% in 2002 to 2005, 34.6% in 2006 to 2010); and fungus accounted for 2.2%. Among GNB, Klebsiella species (53.2%, 84/158) and Escherichia coli (19.6%, 31/158) were common. Staphylococcus aureus (48.5%, 32/66) and viridans streptococci (21.2%, 14/66) were frequently isolated among GPB. The susceptibilities of oxacillin and vancomycin in GPB were 54.8% and 96.9% (51.5% and 95.5% in 2002 to 2005; 34.1% and 90.5% in 2006 to 2010), respectively, whereas in GNB, the susceptibilities of cefotaxime, piperacillin/tazobactam, and imipenem were 73.2%, 77.2%, and 92.6% (75.9%, 82.8%, and 93.4% in 2002 to 2005; 62.8%, 82.9%, 93.8% and in 2006 to 2010), respectively. There were no significant differences in the proportion of etiologic agents or the antimicrobial susceptibilities between the current study and that of the previous two studies from 2002 to 2010. Overall fatality rate was 13.1%. Conclusions: GNB predominated in BSI among children with hemato-oncologic disorders. The etiology of bacteremia and antimicrobial susceptibility were comparable to those of the previous studies. Thus, piperacillin/tazobactam can be used as the initial empirical antimicrobial agent in febrile neutropenia.

목적: 2011년부터 2015년까지 최근 5년간 서울대학교 어린이병원 소아 혈액종양 환자에게 발생한 균혈증의 원인균 분포와 이들의 항생제감수성을 분석하여 경험적 항생제 선택에 실제적인 도움을 얻고자 하였으며 원인균의 분포와 항생제감수성에서 이전 연구와 경향성을 비교하고자 하였다. 방법: 2011년부터 2015년 12월까지 서울대학교 어린이병원에서 입원 치료를 받은 소아 혈액종양 환자들에게 발생한 균혈증에 대하여 의무기록을 후향적으로 분석하였다. 결과: 총 167명의 소아 종양 환자에게 221예의 균혈증이 발생하였고, 229 균주가 분리되었다. 이 중 그람음성균, 그람양성균, 진균이 각각 69.0% (2002-2005년 64.0%, 2006-2010년 63.4%), 28.8%(2002-2005년 31.3%, 2006-2010년 34.6%), 2.2% (2002-2005년 4.7%, 2006-2010년 2.0%)의 분포를 보였다. 그람음성균 중에는 Klebsiella species (53.2%, 84/158), Escherichia coli (19.6%, 31/158), 그람양성균 중에는 Staphylococcus aureus (48.5%, 32/66), viridans streptococci (21.2%, 14/66)가 높은 비율로 분리되었다. 그람양성균의 페니실린, 옥사실린, 반코마이신 감수성률은 각각 13.8%, 54.8%, 96.9% (2002-2005년 16.7%, 51.5%, 95.5%; 2006-2010년 14.3%, 34.1%, 90.5%)이었고, 그람음성균의 세포탁심(cefotaxime), 피페라실린/타조박탐(piperacillin/tazobactam), 이미페넴(imipenem), 겐타마이신(gentamicin), 아미카신(amikacin) 감수성률은 각각 73.2%, 77.2%, 92.6%, 71.0%, 95.2% (2002-2005년 75.9%, 82.8%, 93.4%, 78.4%, 85.8%; 2006-2010년 62.8%, 82.9%, 93.8%, 67.8%, 86.3%)이었다. 본 연구의 원인균 분포 및 항생제감수성률은 과거 연구와 비교하여 차이가 없었다. 전체 환자에서 치사율은 13.1%이었다. 결론: 그람음성균은 소아 혈액종양 환자의 균혈증의 가장 흔한 원인균이다. 균혈증의 원인균과 항생제감수성은 이전 연구들과 다르지 않았다. 연구 결과에 따라 본 연구 기관에서는 예년과 같이 발열을 동반하는 소아 혈액종양 환자에서의 경험적 항생제를 피페라실린/타조박탐으로 투여할 수 있을 것이다.

Keywords

References

  1. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 2005;40 Suppl 4:S240-5. https://doi.org/10.1086/427329
  2. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-32. https://doi.org/10.1056/NEJM199305063281808
  3. Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 Suppl 1:S51-9. https://doi.org/10.1016/j.ijantimicag.2007.06.012
  4. Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 2006;12:217-23. https://doi.org/10.1111/j.1469-0691.2005.01298.x
  5. Aust C, Tolfvenstam T, Broliden K, Ljungman P, Kalin M, Giske CG, et al. Bacteremia in Swedish hematological patients with febrile neutropenia: bacterial spectrum and antimicrobial resistance patterns. Scand J Infect Dis 2013;45:285-91. https://doi.org/10.3109/00365548.2012.735372
  6. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med 1977;62:731-42. https://doi.org/10.1016/0002-9343(77)90876-2
  7. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999;29:490-4. https://doi.org/10.1086/598620
  8. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103-10. https://doi.org/10.1086/374339
  9. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39 Suppl 1:S25-31. https://doi.org/10.1086/383048
  10. Gudiol C, Bodro M, Simonetti A, Tubau F, Gonzalez-Barca E, Cisnal M, et al. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect 2013;19:474-9. https://doi.org/10.1111/j.1469-0691.2012.03879.x
  11. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7. https://doi.org/10.1093/clinids/14.6.1201
  12. Cordonnier C, Buzyn A, Leverger G, Herbrecht R, Hunault M, Leclercq R, et al. Epidemiology and risk factors for grampositive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149-58. https://doi.org/10.1086/345435
  13. Kim SH, Lee YA, Eun BW, Kim NH, Lee JA, Kang HJ, et al. Etiological agents isolated from blood in children with hemato-oncologic diseases (2002-2005). Korean J Pediatr 2007;50:56-64. https://doi.org/10.3345/kjp.2007.50.1.56
  14. Kang JE, Seok JY, Yun KW, Kang HJ, Choi EH, Park KD, et al. Etiological agents in bacteremia of children with hematooncologic diseases (2006-2010): a single center study. Korean J Pediatr Infect Dis 2012;19:131-40. https://doi.org/10.14776/kjpid.2012.19.3.131
  15. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009;49:1-45. https://doi.org/10.1086/599376
  16. Kleinman ME, Chameides L, Schexnayder SM, Samson RA, Hazinski MF, Atkins DL, et al. Pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010;126:e1361-99. https://doi.org/10.1542/peds.2010-2972D
  17. Maki DG, Mermel LA, Kluger D, Narans L, Knasinski V, Parenteau S, et al. The efficacy of a chlorhexidine-impregnated sponge (biopatch) for the prevention of intravascular catheter-related infection: a prospective, randomized, controlled, multicenter study. Present at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, Canada.
  18. Levy I, Katz J, Solter E, Samra Z, Vidne B, Birk E, et al. Chlorhexidine-impregnated dressing for prevention of colonization of central venous catheters in infants and children: a randomized controlled study. Pediatr Infect Dis J 2005;24:676-9. https://doi.org/10.1097/01.inf.0000172934.98865.14
  19. Ho KM, Litton E. Use of chlorhexidine-impregnated dressing to prevent vascular and epidural catheter colonization and infection: a meta-analysis. J Antimicrob Chemother 2006;58:281-7. https://doi.org/10.1093/jac/dkl234
  20. Rivas-Ruiz R, Villasis-Keever MA, Miranda-Novales MG, Castelan-Martinez D, Vivanco-Munoz N, Chico-Barba G, et al. Efficacy of a chlorhexidine-gluconate impregnated patch for prevention of catheter-related infections in pediatric patients: systematic review and meta-analysis. Bol Med Hosp Infant Mex 2011;68:349-55.
  21. Han SB, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, et al. Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia. Infection 2013;41:917-24. https://doi.org/10.1007/s15010-013-0470-7

Cited by

  1. Usefulness of the procalcitonin test in young febrile infants between 1 and 3 months of age vol.61, pp.9, 2018, https://doi.org/10.3345/kjp.2017.06170
  2. Isolated from Children with Bacteremia in 2000–2015 pp.1931-8448, 2018, https://doi.org/10.1089/mdr.2017.0224